{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:09:27Z","timestamp":1762459767510,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2019.08.079","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T16:00:45Z","timestamp":1567872045000},"page":"7029-7040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen"],"prefix":"10.1016","volume":"37","author":[{"given":"Kamran","family":"Haq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Mehdy","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassel","family":"Akache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Gurnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anindita","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazila","family":"Nazemi-Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5538-1363","authenticated-orcid":false,"given":"Michael J.","family":"McCluskie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risini D.","family":"Weeratna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.079_b0005","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.vaccine.2019.08.079_b0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.08.079_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.08.079_b0020","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.08.079_b0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.vaccine.2019.08.079_b0030","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2019.08.079_b0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","article-title":"Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials","volume":"7","author":"Viani","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2019.08.079_b0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ctrv.2012.04.008","article-title":"Current approaches and future directions in the treatment of HER2-positive breast cancer","volume":"39","author":"Hurvitz","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.vaccine.2019.08.079_b0045","first-page":"676","article-title":"Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus","volume":"59","author":"Kass","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2019.08.079_b0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/j.seminoncol.2005.09.006","article-title":"Pox viral vaccine approaches","volume":"32","author":"Arlen","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/596432","article-title":"Strategies for cancer vaccine development","volume":"2010","author":"Vergati","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0060","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.08.079_b0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2019.08.079_b0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.08.079_b0075","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.08.079_b0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis"},{"key":"10.1016\/j.vaccine.2019.08.079_b0085","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0090","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1158\/0008-5472.CAN-06-4317","article-title":"Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus","volume":"67","author":"Bourbeau","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2019.08.079_b0095","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/10430340050032438","article-title":"Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy","volume":"11","author":"Oualikene","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2019.08.079_b0100","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.vaccine.2008.02.026","article-title":"Archaeosome adjuvants: Immunological capabilities and mechanism(s) of action","volume":"26","author":"Krishnan","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.079_b0105","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/14760584.2016.1195265","article-title":"Archaeal lipid vaccine adjuvants for induction of cell-mediated immunity","volume":"15","author":"Haq","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.079_b0110","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1080\/21645515.2017.1316912","article-title":"Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity","volume":"13","author":"McCluskie","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.08.079_b0115","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1080\/21645515.2017.1423154","article-title":"Safety and biodistribution of sulfated archaeal glycolipid archaeosomes as vaccine adjuvants","volume":"14","author":"Akache","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.08.079_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208067","article-title":"Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice","volume":"13","author":"Akache","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.08.079_b0125","first-page":"831","article-title":"Identification and characterization of mouse Erbb2 gene in silico","volume":"23","author":"Katoh","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1472-6750-6-43","article-title":"The cumate gene-switch: a system for regulated expression in mammalian cells","volume":"6","author":"Mullick","year":"2006","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jviromet.2014.08.013","article-title":"Establishment and validation of new complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture","volume":"208","author":"Gilbert","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.08.079_b0140","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/0008-5472.CAN-06-3290","article-title":"Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors","volume":"67","author":"Nava-Parada","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2019.08.079_b0145","first-page":"381","article-title":"Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors","volume":"30","author":"Masuelli","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/sj.gt.3302232","article-title":"T-cell response to adenovirus hexon and DNA-binding protein in mice","volume":"11","author":"McKelvey","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2019.08.079_b0155","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/mt.2008.141","article-title":"The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens","volume":"16","author":"Schirmbeck","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2019.08.079_b0160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.carres.2009.10.011","article-title":"Development of new glycosylation methodologies for the synthesis of archaeal-derived glycolipid adjuvants","volume":"345","author":"Whitfield","year":"2010","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2019.08.079_b0165","unstructured":"Whitfield DM. C, Sprott G. Dennis; CA, Krishnan L. Sulfated-glycolipids as adjuvants for vaccines. WO 2016\/004512 A1. 2016 Jan 14, 2016."},{"key":"10.1016\/j.vaccine.2019.08.079_b0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0076-6879(03)73011-0","article-title":"Archaeobacterial ether lipid liposomes as vaccine adjuvants","volume":"373","author":"Sprott","year":"2003","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4049\/jimmunol.171.1.27","article-title":"Cutting edge: rapid in vivo killing by memory CD8 T cells","volume":"171","author":"Barber","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2019.02.041","article-title":"A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations","volume":"561","author":"Jia","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2019.08.079_b0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2018.04.016","article-title":"Treatment of advanced HER2-positive breast cancer: 2018 and beyond","volume":"67","author":"Pond\u00e9","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.vaccine.2019.08.079_b0190","doi-asserted-by":"crossref","first-page":"64431","DOI":"10.18632\/oncotarget.7043","article-title":"Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer","volume":"7","author":"de Melo Gagliato","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2019.08.079_b0195","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2015.5482","article-title":"Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer: role for immune monitoring","volume":"2","author":"Datta","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0200","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fphar.2016.00356","article-title":"Restoring lost anti-HER-2 Th1 immunity in breast cancer: A crucial role for Th1 cytokines in therapy and prevention","volume":"7","author":"Nocera","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0205","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/jvh.12856","article-title":"Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens","volume":"25","author":"Young","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.vaccine.2019.08.079_b0210","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12033-013-9723-z","article-title":"Flagellin in fusion with human rotavirus structural proteins exerts an adjuvant effect when delivered with replicating but non-disseminating adenovectors through the intrarectal route","volume":"56","author":"Girard","year":"2014","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00720-16","article-title":"Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses","volume":"91","author":"Crosby","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0220","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1089\/hum.2015.055","article-title":"Replication-competent viruses as cancer immunotherapeutics: emerging clinical data","volume":"26","author":"Zamarin","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2019.08.079_b0225","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2019.08.079_b0230","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/cgt.2012.95","article-title":"Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers","volume":"20","author":"Choi","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2019.08.079_b0235","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.vaccine.2013.11.045","article-title":"Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines","volume":"32","author":"Dean","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.079_b0240","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0245","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.08.079_b0250","article-title":"Combination adenovirus and protein vaccines prevent infection or reduce viral burden after heterologous clade C simian-human immunodeficiency virus mucosal challenge","volume":"92","author":"Malherbe","year":"2017","journal-title":"J Virol"},{"issue":"47","key":"10.1016\/j.vaccine.2019.08.079_b0255","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2019.07.010","article-title":"Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization","volume":"37","author":"Stark","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.079_b0260","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im2009s82","article-title":"ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas","author":"Quaglino","year":"2008","journal-title":"Curr Protoc Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:23Z","timestamp":1759401443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19311685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":52,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X19311685"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}